Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 11/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20047562 | 0.87 | ATM (0.33) | CASRMAPTATML3MBTL1 | |
| SCHEMBL20049289 | 0.84 | RAB9A (0.43) | MAPTGPR3ATML3MBTL1ALDH1A1 | |
| SCHEMBL20047537 | 0.80 | TLR8 (0.46) | CASRMAPT | |
| SCHEMBL12109097 | 0.77 | XIAP (0.45) | CASRMAPTATML3MBTL1KDM4E | |
| SCHEMBL28392628 | 0.73 | CASR (0.40) | CASRKDM4EALDH1A1HPGD | |
| SCHEMBL9193166 | 0.72 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL26462924 | 0.69 | LMNA (0.47) | MAPTL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL12341036 | 0.68 | MIF (0.47) | MAPTGPR3TNKSTNKS2KDM4E | |
| SCHEMBL20043216 | 0.68 | CASR (0.37) | CASRMAPTKDM4EALDH1A1CYP2C9 | |
| SCHEMBL12354251 | 0.67 | ALDH1A1 (0.57) | MAPTATML3MBTL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | CASR 879/4885MAPT 4191/4885GPR3 132/4885 |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | GPBAR1, SLC10A1, NR1H4 | CASR 879/4885MAPT 4191/4885GPR3 132/4885 |
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | CASR 879/4885MAPT 4191/4885GPR3 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.